HomeInsightsPE

Astrazeneca Pharma India Ltd PE Ratio

Astrazeneca Pharma India Ltd PE Ratio

stocks purchased

₹ 2.0 Cr

Volume Transacted

(Nov 14, 2024)

stocks purchased

3.0 K

Stocks Traded

(Nov 14, 2024)

Last Updated on: Nov 14, 2024

Image

Astrazeneca Pharma India Ltd

NSE: ASTRAZEN

PE

136.1

Last updated on: Nov 14, 2024

Key Highlights

  • The P/E Ratio of Astrazeneca Pharma India Ltd is 136.1 as of 14 Nov 15:30 PM.
  • The P/E Ratio of Astrazeneca Pharma India Ltd changed from 91.8 on March 2019 to 82.4 on March 2024 . This represents a CAGR of -1.78% over 6 years. .
  • The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 6740 as of 14 Nov 15:40.
  • The PE Ratio of Pharmaceuticals Industry has changed from 28.2 to 27.1 in 5 years. This represents a CAGR of -0.79%.
  • The PE Ratio of Automobile industry is 20.2. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.3. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.7. The PE Ratio of Textiles industry is 37.6 in 2024.

Historical P/E Ratio of Astrazeneca Pharma India Ltd

No data available

Company Fundamentals for Astrazeneca Pharma India Ltd

No data available

Image

Astrazeneca Pharma India Ltd

NSE: ASTRAZEN

PRICE

₹ 6740.65

-392.45 (-5.50%)

stock direction

Last updated on: Nov 14 03:40 PM

Market Price Over Time

1M

1Y

3Y

5Y

Monitoring Astrazeneca Pharma India Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
13 Nov 20247133.1
12 Nov 20247410.5
11 Nov 20247252.7
08 Nov 20247317.65
07 Nov 20247517
06 Nov 20247608.65
05 Nov 20247478
04 Nov 20247379.4
01 Nov 20247550.3
31 Oct 20247606.7

BlinkX Score for Astrazeneca Pharma India Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Astrazeneca Pharma India Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of P/E Ratio

Key Valuation Metric of Astrazeneca Pharma India Ltd

No data available

No data available

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Astrazeneca Pharma India Ltd

No data available

* All values are in crore

Historical Revenue of Astrazeneca Pharma India Ltd

No data available

* All values are in crore

Historical EBITDA of Astrazeneca Pharma India Ltd

No data available

* All values are in crore

Historical Net Profit of Astrazeneca Pharma India Ltd

No data available

* All values are in crore

Historical Dividend Payout of Astrazeneca Pharma India Ltd

No data available

* All values are in %

About Astrazeneca Pharma India Ltd

  • AstraZeneca Pharma India (APIL) was incorporated on July 11, 1979.
  • The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
  • The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
  • Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

Astrazeneca Pharma India Ltd News Hub

News

AstraZeneca slumps on recording dismal Q1 performance

Revenue from operations jumped 31.15% year on year (YoY) to Rs 387.52 crore in the quarter...

Read more

2024-08-08 00:00:00

News

Astrazeneca Pharma India reports standalone net loss of Rs 11.79 crore in the June 2024 quarter

Net loss of Astrazeneca Pharma India reported to Rs 11.79 crore in the quarter ended June ...

Read more

2024-08-08 00:00:00

News

Astrazenenca Pharma gets CDSCO nod to import Durvalumab solutions

Durvalumab (IMFINZI) in combination with chemotherapy as neoadjuvant treatment, followed b...

Read more

2024-09-24 00:00:00

News

Astrazeneca Pharma India Ltd leads gainers in 'A' group

Sapphire Foods India Ltd, Godawari Power & Ispat Ltd, Firstsource Solutions Ltd and Nation...

Read more

2024-09-24 00:00:00

News

Volumes spurt at Astrazeneca Pharma India Ltd counter

Sapphire Foods India Ltd, Godawari Power & Ispat Ltd, Schneider Electric Infrastructure Lt...

Read more

2024-09-24 00:00:00

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Astrazeneca Pharma India Ltd

What is the current PE Ratio of Astrazeneca Pharma India Ltd?

The Current PE Ratio of Astrazeneca Pharma India Ltd is 136.13 as on 14 Nov 2024.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 14 Nov 2024.

What was the PE Ratio of Astrazeneca Pharma India Ltd last year?

The PE Ratio of Astrazeneca Pharma India Ltd was 81.75 last year, now the PE ratio is 136.13, showing a year-on-year growth of 66.5%.

What does the PE Ratio of Astrazeneca Pharma India Ltd indicate about its stock?

The PE Ratio of Astrazeneca Pharma India Ltd is 136.13. This ratio indicates that investors are willing to pay 136.13 times the earnings per share for each share of Astrazeneca Pharma India Ltd.

What is the PE Ratio Growth of Astrazeneca Pharma India Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Astrazeneca Pharma India Ltd grew by 66.5% whereas, the EPS ratio grew by -446.8.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*